Three AI deals kick off #JPM22 week­end; Can Sil­i­con Val­ley change how sci­ence gets fund­ed?; Spe­cial re­port: 2021 new drug ap­provals; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

A no­table trend in this week’s in­stall­ment of news is a hearty plate of ap­pe­tiz­er-sized deals as we lead in­to the JP Mor­gan con­fer­ence. As per End­points tra­di­tion, we have sched­uled three days of vir­tu­al pan­els fea­tur­ing an ex­cel­lent line­up of bio­phar­ma in­sid­ers to talk about the top trends they will be watch­ing in 2022. You don’t want to miss it.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER